Biological Evaluation Report (BER) for Medical Devices

What a Biological Evaluation Report Is

The Biological Evaluation Report, usually shortened to BER, is the document that records how the available evidence supports biological safety for the finished medical device. Under ISO 10993, it sits at the end of the biological evaluation flow rather than at the beginning.

That means the BER is not where strategy should be invented for the first time. It is where the evidence is weighed, the limitations are acknowledged, and the final endpoint-by-endpoint conclusions are written clearly enough for FDA, a notified body, or another reviewer to follow.

What a BER Needs to Do Under ISO 10993

A strong BER usually needs to do five things well:

• Describe the actual finished device: not an abstract material list detached from manufacturing, sterilization, packaging, or real patient contact.
• Show the evidence base clearly: literature, prior biological testing, chemistry, toxicology, equivalence reasoning, and any new data used for the evaluation.
• Address each relevant endpoint: including why endpoints are concluded, waived, unresolved, or supported by chemistry rather than direct testing.
• Connect to the wider file: especially the BEP, risk-management logic, and any regulatory pathway-specific framing.
• Reach a defendable overall conclusion: the reader should understand why the evidence package is enough for this device and this intended use.

What Reviewers Usually Notice First

Reviewers do not only look for whether a BER exists. They look for whether it reads like a real scientific evaluation or just a document wrapper around disconnected inputs. Weak reports often show one or more of these patterns:

• endpoint conclusions that sound generic and could apply to almost any device
• waived endpoints with little or no device-specific rationale
• chemistry or TRA outputs that never get integrated back into the final biological argument
• legacy text that no longer matches the current device, supplier base, or sterilization state
• conclusions that do not align with the BEP or risk-management file

Where Teams Commonly Get Stuck

Many teams have more evidence than they realize, but the BER still feels weak because the evidence is not being translated into endpoint logic. That is especially common when literature, chemistry, and prior testing all exist, but nobody has closed the reasoning loop between those inputs and the final biological safety conclusion.

It is also common to see the opposite problem: a report exists, but the scope was never planned clearly in the first place. In that case the BER becomes a repair job for earlier BEP or strategy gaps.

When You Need BER Drafting vs BER Review

If the report does not exist yet, or the current text is too generic to salvage efficiently, the right path is usually the BER drafting service. That is the fit when the evidence must be structured into a fresh reviewer-facing document.

If a report already exists and the main question is whether the endpoint logic, chemistry integration, or conclusions are strong enough, the better fit is often the BER review service. That is the faster path when you need a specialist check before submission or before more internal revision time is spent.

When the Problem Is Broader Than the BER

Sometimes the report is not the only issue. The real weakness may span the BEP, BER, TRA, materials story, reviewer comments, and the broader submission narrative together. When that is the case, it is usually better to start with a submission gap review or the broader biocompatibility consulting overview instead of forcing the whole problem into one document title.